Prostate Cancer

November 9, 2020 - Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in The Journal of Urology® , an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer. "In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer," according to the report by senior author Peter R. Carroll, MD, MPH, of University of California, San Francisco (UCSF) and colleagues. During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging and repeat biopsies. If symptoms develop, or if tests indicate the cancer is more aggressive, active treatment such as surgery or radiation may b...

Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia Men undergoing active surveillance for prostate cancer have very low rates - one percent or less—of cancer spread (metastases) or death from prostate cancer, according to a recent study published in The Journal of Urology , an official journal of the American Urological Association (AUA). "In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer," according to the report by senior author Peter R. Carroll, MD, MPH, of University of California, San Francisco (UCSF) and colleagues. During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging and repeat biopsies. If symptoms develop, or if tests indicate the cancer is more aggressive, active treatment such as surg...

Al Roker Going to Tell Prostate Cancer 'You're Fired' | PEOPLE.com Skip to content Top Navigation Close Explore PEOPLE.com Profile Menu Follow us Close Share options Close View image Al Roker Thanks Fans for Support After Diagnosis, Says He's Going to Tell Prostate Cancer 'You're Fired' this link is to an external site that may or may not meet accessibility guidelines.

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top medical stories of the week. A transcript of the podcast is below the summary. This week's topics include household transmission of COVID, monoclonal antibodies for treatment of COVID, kindergarten preparedness and long term benefits, and active surveillance for Black men with low risk prostate cancer. Program notes: 0:59 Monoclonal antibodies for treatment of COVID 1:58 Antibody prevented hospitalization in many 2:57 Cost less than hospitalization? 3:40 Kindergarten readiness 4:40 Reduction in odds of being overweight 5:40 Need resources invested in preschool 6:44 Household transmission of COVID 7:44 75% of secondary infections within 5 days 8:42 Wear a face mask even within households 9:40 Active surveillance among Black men wit...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top medical stories of the week. A transcript of the podcast is below the summary. This week's topics include household transmission of COVID, monoclonal antibodies for treatment of COVID, kindergarten preparedness and long term benefits, and active surveillance for Black men with low risk prostate cancer. Program notes: 0:59 Monoclonal antibodies for treatment of COVID 1:58 Antibody prevented hospitalization in many 2:57 Cost less than hospitalization? 3:40 Kindergarten readiness 4:40 Reduction in odds of being overweight 5:40 Need resources invested in preschool 6:44 Household transmission of COVID 7:44 75% of secondary infections within 5 days 8:42 Wear a face mask even within households 9:40 Active surveillance among Black men wit...

Read the Full Video Transcript Alicia Morgans:  Hi, my name is Alicia Morgans. I'm a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago, in the United States. I'm so excited to have here with me today, Dr. Karim Fizazi, who's a GU medical oncologist and a professor of oncology at Gustave Roussy in Paris, France. Thank you so much for being here with me today, Karim. Karim Fizazi:   Thank you, Alicia. Always a pleasure. Alicia Morgans:   Wonderful. So I wanted to speak with you a little bit about the AMG 160 presentation that was recently made at ESMO. And you are the anchor author on that presentation and certainly a lead investigator in the work. Can you tell us a little bit, before we get into the trial itself, what the BiTE platform is? So that folks from the GU oncology world can start to become more familiar. Karim Fizazi:   Sure. So BiTEs are indeed, new compounds, with basically two hands, if you will. For exa...

San Francisco, CA (UroToday.com) -- Doctors and biostatisticians at the University of Michigan Rogel Cancer Center have led the development and validation of a staging system to better predict outcomes and inform treatment decisions for men diagnosed with non-metastatic prostate cancer. Although it is one of the most common cancers worldwide, prostate cancer remains one of the few major cancers for which the familiar, numerical staging system -; ranging from stage 1 to stage 4 -; has not been adopted into national guidelines for treatment or for the testing of new medicines in clinical trials. The new proposed system -; dubbed STAR-CAP -; which appears in JAMA Oncology, draws on patient, tumor and outcomes data from nearly 20,000 patients from 55 centers in the U.S., Canada and Europe to create a robust model with strong prognostic power. "Localized prostate cancer is sometimes less aggressive, sometimes more -; and whether we're patients, physicians or researchers, we all w...